Aetion

Aetion

Leader in delivering real-world evidence (RWE) and outcomes-based analytics solutions to life science companies and payers.

Based in New York City, Aetion (pronounced eh-tee-ahn) is a leading healthcare technology company that delivers the real-world analytics and evidence needed for value-based care. With its patented rapid-cycle analyticsTM technology, the Aetion Evidence Platform utilizes the everyday clinical and financial interactions of the healthcare system to unlock essential evidence about the effectiveness and value of medical treatments. Founded by Harvard Medical School faculty members and top big data technologists, Aetion enables payers and providers to collaborate with biopharmaceutical and medical device companies in real-time to develop therapeutic insights and make smart choices in patient care. The company is backed by Flare Capital Partners, Lakestar, Oxeon Ventures and other leading individual health technology investors. Learn more at www.aetion.com.

Aetion has raised a total of $74.6M in funding over 3 rounds. Their latest funding was raised on Feb 5, 2019 from a Series B round.

Aetion has 1 registered patent in the 'Computing; Calculating' category. Additionally, Aetion has registered 2 trademarks with the most popular class being 'Scientific and technological services'.

Timeline

February 5, 2019

Their latest funding was raised on Feb 5, 2019 from a Series B round.

2019

This year, Aetion is projected to spend $146.8K on IT.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Aetion funding round, February 2019
27,000,000
February 2019
4 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
AlleyWatch
August 26, 2020
AlleyWatch
The Pulse of New York Tech
Conor Hale
May 19, 2020
FierceBiotech
The FDA is tapping its real-world data partner Aetion for new research tracking the spread of COVID-19. The project will include gathering and sifting through information on diagnostic and treatment patterns, to help the agency better understand the natural course of the novel coronavirus.
Alex Keown
May 19, 2020
BioSpace
Research conducted under the collaboration will support FDA objectives to explore the natural history of the disease, as well as treatment and diagnostic patterns through the use of relevant and new data sources.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.